Background: KALRN (kalirin RhoGEF kinase) is mutated in a wide range of cancers.
Introduction
Recently, immunotherapy has achieved success in treating various cancers [1] [2] [3] [4] . In particular, the immune checkpoint blockade (ICB), such as inhibition of CTLA-4 (cytotoxic T-lymphocyteassociated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed cell death 1 ligand), has been used for therapy of many advanced malignancies 5 . Nevertheless, many cancer patients failed to respond to the immunotherapy. To this end, numerous studies have identified certain genetic or genomic features that are associated with cancer immunotherapy response, such as PD-L1 expression 6 and tumor mutation burden (TMB) 7 . The mutations of certain genes, such as TP53 8 and ARID1A 9 , have been associated with cancer immunotherapy response.
KALRN (kalirin RhoGEF kinase) encodes a protein which activates specific Rho GTPase family members to regulate neurons and actin cytoskeleton 10 . This gene are mutated in a wide type of cancers 11 , e.g., melanoma, lung cancer, uterine corpus endometrial carcinoma (UCEC), glioblastoma multiforme (GBM), and colorectal cancer (CRC). Nevertheless, very few reports of the association between KALRN mutations and cancerogenesis have been published 12, 13 .
In this study, we investigated the associations between KALRN mutations and anti-tumor immune signatures (NK cells, CD8+ T cells, and immune cytolytic activity (ICA)) in 10 individual cancer types (CESC, COAD, ESCA, GBM, PRAD, READ, SARC, SKCM, STAD, and UCEC) and in their pan-cancer by analyzing the Cancer Genome Atlas (TCGA, https://cancergenome.nih.gov) cohorts. In these cohorts, we also explored the associations between KALRN mutations and cancer immunotherapy response-related biomarkers, such as PD-L1 expression and TMB. Moreover, based on four cancer cohorts receiving immunotherapy, we investigated the association between KALRN mutations and cancer immunotherapy response. Furthermore, we validated our findings from bioinformatics analysis by performing in vitro experiments in three tumor cell lines (MGC803, SJSA1, and SW620). Our study demonstrated that KALRN mutations may promote anti-tumor immunity and cancer immunotherapy response and thus could be a useful biomarker for stratifying cancer patients responsive to immunotherapy.
Materials and Methods

Materials
We downloaded the datasets for the 10 TCGA cancer cohorts from the genomic data commons data portal (https://portal.gdc.cancer.gov/). The 10 cancer cohorts included cervical squamouscell carcinoma and endocervical adeno-carcinoma (CESC), colon adeno-carcinom (COAD), Esophageal Carcinoma (ESCA), Glioblastoma Multiforme (GBM), Prostate Adenocarcinoma (PRAD), Rectum Adenocarcinoma (READ), Sarcoma (SARC), Skincutaneous Melanoma (SKCM), Stomach Adenocarcinoma (STAD), and Uterine Corpus Endometrial Carcinoma (UCEC). For each cancer type, we obtained its gene somatic mutations, RNA-Seq gene expression profiles, protein expression profiles, and clinical data. For pan-cancer, we downloaded the related datasets from UCSC (https://xenabrowser.net/datapages/). We obtained the data for predicted neoantigens in the TCGA cancer cohorts from the publication 14 , in which a total of 6 cancer types (CESC, PRAD, GBM, STAD, SKCM, UCEC) had predicted neoantigen data available. For the four cancer cohorts receiving anti-PD-1/PD-L1/CTLA-4 immunotherapy (Allen cohort 1 , Hugo cohort 15 , Riaz cohort 16 ), and Rizvi cohort 17 ), we obtained their genomics and clinical data from the associated publications. A summary of these datasets is shown in Supplementary Table S1.
Evaluation and Comparisons of Immune Signature Enrichment Scores
We calculated the enrichment score of an immune signature in a tumor sample by the singlesample gene-set enrichment analysis (ssGSEA) 18 of the marker genes of the immune signature.
Three immune signatures were analyzed, including NK cells (marker genes KLRC1 and KLRF1), CD8+ T cells (CD8A), and immune cytolytic activity (PRF1 and GZMA) 14 . The comparisons of immune signature enrichment scores between two classes of samples were performed using the Mann-Whitney U test (one-sided). As well, we compared the ratios of immune-stimulatory to immune-inhibitory signatures (CD8+/CD4+ regulatory T cells, M1/M2 macrophages, and pro-/anti-inflammatory cytokines) between two classes of samples using the Mann-Whitney U test (one-sided). The ratios were the mean expression levels of immune-stimulatory signature marker genes over those of immune-inhibitory signature marker genes. We carried out these analyses using R programming software (ssGSEA scores were calculated using R package "GSVA" 18 ).
Comparisons of the Expression Levels of Genes and Proteins between
Two Classes of Samples
We compared the expression levels of genes and proteins between two classes of samples using Student's t test. The normalized RNA-Seq gene expression values (RSEM) were log2 transformed before the analyses, and the downloaded normalized protein expression data (RPPA) were used to perform the analyses.
Survival Analyses
We used Kaplan-Meier survival curves to exhibit the survival time differences. The significance of survival time differences was evaluated by the log-rank test. The survival analyses were performed using R function "survfit" in "survival" package.
In vitro Experiments
Antibodies, Reagents, and Cell lines
All antibodies were used at a dilution of 1:1000 unless otherwise specified. Anti-PD-L1 (ab213524) was purchased from Abcam (Burlingame, CA). GAPDH (sc32233) was purchased from Santa Cruz Biotechnology. Anti-MSH2 (15520-1-AP) was purchased from Proteintech Group (Rosemont, IL, USA.). Anti-KALRN (BS3514) was purchased from Bioworld 
Knockdown of KALRN with Small Interfering RNA (siRNA)
Cancer cells were transfected with KALRN siRNA or control siRNA using Effectene Transfection Reagent (Qiagen, B00118) following the manufacturer's instructions. The media was replaced after 24h incubation with fresh medium and the cells were maintained for another 24h. The transfection efficiency was detected by Quantitative PCR or Western blot. KALRN siRNA and control siRNA were synthetized by GenePharma (Shanghai, China). Their sequences were: KALRN siRNA (1, 5'-GCUUCCACUGAAGUACCUATT -3' (sense) and 5'-UAGGUAC UUCAGUGGAAGCTT-3' (antisense); 2, 5'-GCAAUCGCCCAUUGAGUAUTT-3' (sense) and 5'-AUACUCAAUGGGCGAUUGCTT -3' (antisense); 3, 5'-GCUUCGACCUUGGACAC UUTT-3' (sense) and 5'-AAGUGUCCAAGGUCGAAGCTT-3' (antisense)), and control siRNA ( 5'-UUCUCCGAACGUGUCACGUTT -3' (sense) and 5'-ACGUGACACGUUCGGA GAATT -3' (antisense)).
Western blotting
Cell extracts were generated using lysis buffer supplemented with protease inhibitor cocktail immediately before use. Proteins were denatured by adding 6× SDS sample buffer and boiled at 100°C for 10 min, and were then separated by SDS-PAGE. After electrophoresis, proteins were electrotransferred onto nitrocellulose membranes. The membranes were then blocked in 5% nonfat dry milk buffer at a room temperature for 1h and were then incubated overnight at 4°C with specific antibodies. Binding of the primary antibody was detected using peroxidaseconjugated secondary antibodies and a SuperSignal West Dura chemiluminescent substrate kit (Thermo Scientific, 34075) according to the manufacturer's instructions. The western blotting result was semi-quantified using ImageJ software to measure the intensities of the bands. The band densities were normalized to background and the relative optical density ratios were calculated relative to the housekeeping gene GAPDH.
Quantitative PCR
The total RNA was extracted from cells and was reversely transcribed to cDNA. Quantitative PCR was performed with the BioRad CFX96 ouchTM Real-Time PCR Detection System (BioRad, CA) using iQTM SYBR1 Green supermix (BioRad, CA). The threshold cycle numbers were obtained using BioRad CFX manager software. The program for amplification was 1 cycle of 95°C for 2 min followed by 40 cycles of 95°C for 10s, 60°C for 30s, and 72°C for 30s. The relative amount of each gene was normalized to the amount of GAPDH. The primer sequences were：hKALRN, 5'-GATTGTCATCTTCAGTGA-3'(forward) and 5'-AGGACCAAGTAATTC ATC-3' (reverse); hGAPDH, 5'-TGTGGGCATCAATGGATTTGG-3' (forward) and 5'-ACAC CATGTATTCCGGGTCAAT-3' (reverse).
Co-culture of Tumor Cells with NK92 Cells
The transwell chamber (Corning Inc, NY, USA) was inserted into a 6-well plate to construct a co-culture system. Tumor cells (MGC803, SJSA1, and SW620) were seeded on the 6-well plate at a density of 5×10 4 cells/well, and NK92 cells were seeded on the membrane (polyethylene terephthalate, pore size, 0.4 μm) of the transwell chamber at a density of 5×10 4 cells/chamber.
Tumor cells and NK92 cells were co-cultured in a humidified incubator at 37°C and a 5% CO2 atmosphere for 48h.
EdU Proliferation Assay
After the co-culture of tumor cells with NK92 cells for 48h, the proliferation capacity of NK92 cells was measured by an EdU (5-ethynyl-2 '-deoxyuridine, Invitrogen, CA, USA) proliferation assay. NK92 cells were plated in 96-well plates with a density of 2×10 3 cells/well for 24h.
Before fixation, permeabilization, and EdU staining, the cells were incubated with 10 μM EdU at 37°C for 24h. The cell nuclei were stained with DAPI at a concentration of 1 μg/ml for 20 min.
The proportion of the NK92 cells incorporating EdU was determined with fluorescence microscopy. Each assay was performed in triplicate wells.
Results
KALRN Mutations Promote Anti-Tumor Immunity in Cancer
We found that the immune signatures (NK cells, CD8+ T cells, and ICA) consistently displayed higher enrichment levels in KALRN-mutated than in KALRN-wildtype cancers in the pan-cancer analysis (Mann-Whitney U test, P<0.001) ( Figure 1A) . Moreover, the NK cells, CD8+ T cells, and ICA enrichment scores were significantly higher in KALRN-mutated than in KALRNwildtype cancers in 4, 5, and 5 individual cancer types, respectively (Mann-Whitney U test, P<0.05) ( Figure 1A ). Furthermore, we compared the ratios of immune-stimulatory signatures to immune-inhibitory signatures in pan-cancer and in individual cancer types. We found that the ratios (CD8+/CD4+ regulatory T cells, M1/M2 macrophages, and pro-/anti-inflammatory cytokines) were remarkably higher in KALRN-mutated than in KALRN-wildtype cancers in pancancer and in multiple individual cancer types (Mann-Whitney U test, P<0.05) ( Figure 1B ). The
EdU proliferation assay showed that the NK cells co-cultured with KALRN-knockdown tumor cells had significantly stronger proliferation capacity compared to the NK cells co-cultured with KALRN-wildtype tumor cells ( Figure 1C ). Taken together, these data suggest that KALRN mutations enhance anti-tumor immunity in cancer.
KALRN Mutations Are Associated with Increased TMB and the
Microsatellite Instability (MSI) or DNA Damage Repair Deficiency Genomic
Properties in Cancer
TMB has been recognized as a predictive biomarker for cancer immunotherapy response 19 . We found that KALRN-mutated cancers exhibited significantly higher TMB (defined as the total count of gene somatic mutations) than KALRN-wildtype cancers in pan-cancer and in all 10 individual cancer types (Mann-Whitney U test, P<0.01) (Figure 2A ). In addition, KALRNmutated cancers displayed more predicted neoantigens 14 than KALRN-wildtype cancers in pancancer and in 5 individual cancer types (Mann-Whitney U test, P<0.01) (Figure 2A ). Among the 5 cancer types (COAD, ESCA, READ, STAD, and UCEC) with a prevalent MSI subtype, MSI-high (MSI-H) cancers had significantly higher mutation rates of KALRN than MSIlow (MSI-L) and microsatellite stable (MSS) cancers in pan-cancer and in 4 individual cancer types (Fisher's exact test, P<0.01) ( Figure 2B ). Moreover, we found that KALRN mutations cooccurred with mutations of DNA mismatch repair pathway genes (PMS1, PMS2, MLH1, MSH2, MSH3, and MSH6) and DNA replication and repair genes (POLD1 and POLE) in pan-cancer and in multiple individual cancer types (Fisher's exact test, P<0.05) ( Figure 2C ). By analyzing the TCGA protein expression profiling datasets with MSH2 and MSH6 expression values available, we found that MSH2 and MSH6 were downregulated in KALRN-mutated versus KALRNwildtype cancers in UCSC and MSH6 was downregulated in KALRN-mutated cancers in COAD (Student's t test, P<0.05). Furthermore, in vitro experiments showed that MSH2 expression was reduced in KALRN-knockdown than in KALRN-wildtype tumor cells (MGC803, SJSA1, and SW620) ( Figure 2D ). Overall, these results suggest the significant association between KALRN mutations and deficient DNA damage repair that could explain the significantly increased TMB in KALRN-mutated cancers.
Associations of the KALRN Downstream Target Rho Gtpases with TMB,
DNA Damage Repair Pathways, and Tumor Immunity
KALRN is a member of the Rho-GEFs that activate Rho GTPases by promoting their GDP/GTP exchange 20 . As a result, KALRN inactivation may compromise the activation of Rho GTPases.
In fact, KALRN expression was significantly downregulated in KALRN-mutated versus KALRNwildtype cancers in the pan-cancer analysis (Student's t test, P=1.11×10 -5 ), suggesting that KALRN mutations are inactivating mutations that impair KALRN activation. Network analysis by STRING 21 showed that KALRN interacted with multiple members of Rho GTPases, including RAC1, RAC2, RAC3, RHOA, RHOB, RHOC, RHOD, RHOG, and CDC42 ( Figure   3A ). Moreover, we found that KALRN mutations likely co-occurred with mutations of these Rho GTPase genes in pan-cancer and in 8 individual cancer types (Fisher's exact test, P<0.05) ( Figure   3B ). Previous studies demonstrated that Rho GTPases may play a role in regulating the DNA damage response 19 . As expected, Rho GTPase gene-mutated cancers had significantly higher TMB than Rho GTPase gene-wildtype cancers in pan-cancer and in 8 individual cancer types (Mann-Whitney U test, P<0.01) ( Figure 3C ). Rho GTPase gene-mutated cancers exhibited more predicted neoantigens 14 than Rho GTPase gene-wildtype cancers in pan-cancer and in 5 individual cancer types (Mann-Whitney U test, P<0.05) ( Figure 3C ). The mutations of Rho GTPase genes co-occurred with the mutations of DNA damage repair pathway genes (PMS1, PMS2, MLH1, MSH2, MSH3, MSH6, POLD1, and POLE) in pan-cancer and in multiple individual cancer types (Fisher's exact test, P<0.05) ( Figure 3D ). Moreover, the mutations of Rho GTPase genes more frequently occurred in MSI-H than in MSI-L/MSS cancers in pancancer and in 2 individual cancer types (STAD and COAD) (Fisher's exact test, P<0.05) ( Figure   3E ). Collectively, these results confirmed the important role of Rho GTPases in mediating DNA damage repair pathways.
Because Rho GTPase deficiency may cause DNA damage repair deficiency that in turn results in increased TMB and neoantigens, we expected that Rho GTPase gene-mutated cancers would display enhanced anti-tumor immune signatures. As expected, the three immune signatures (NK cells, CD8+ T cells, and ICA) were consistently stronger in Rho GTPase gene-mutated than in Rho GTPase gene-wildtype cancers in pan-cancer (Mann-Whitney U test, P<0.01), as well as in diverse individual cancer types (Mann-Whitney U test, P<0.05) ( Figure 3F ). Moreover, Rho GTPase gene-mutated cancers had significantly higher ratios of immune-stimulatory signatures to immune-inhibitory signatures (CD8+/CD4+ regulatory T cells, and M1/M2 macrophages) in pan-cancer and in diverse individual cancer types (Mann-Whitney U test, P≤0.05) ( Figure 3F ).
Together, these data suggest that the significant correlations of KALRN mutations with increased TMB/neoantigens, deficient DNA damage repair pathways, and enhanced anti-tumor immune infiltrates could be consequences of the deregulation of Rho GTPases targeted by KALRN.
KALRN Mutations are Associated with Elevated PD-L1 Expression in
Cancer and Favorable Cancer Immunotherapy Response
We found that PD-L1 showed significantly higher expression levels in KALRN-mutated than in KALRN-wildtype cancers in pan-cancer and in 4 individual cancer types (Student's t test, P<0.05) ( Figure 4A ). Furthermore, in vitro experiments showed that PD-L1 expression was significantly upregulated in KALRN-knockdown versus KALRN-wildtype tumor cells (MGC803, SJSA1, and SW620) ( Figure 4B ). These data suggest that PD-1-PD-L1-directed immunotherapy is likely to be more effective against KALRN-mutated cancers, since PD-L1 expression is a biomarker for the active response to anti-PD-1/PD-L1 immunotherapy 6 . To prove this hypothesis, we investigated the association between KALRN mutations and ICB therapy response in four cancer cohorts receiving anti-PD-1/PD-L1/CTLA-4 immunotherapy, including Allen cohort 1 (melanoma), Hugo cohort 22 (melanoma), Riaz cohort 16 (melanoma), and Rizvi cohort 17 (lung cancer). We found that KALRN-mutated cancers had significantly higher response rates than KALRN-wildtype cancers in these cohorts (37.04% versus 10.96% in Allen cohort, 45% versus 11.76% in Hugo cohort, 80% versus 27.5% in Riaz cohort, and 100% versus 40.74% in Rizvi cohort) (Fisher's exact test, P<0.1) ( Figure 4C ). Because of the appreciably higher response rates, KALRN-mutated cancers displayed a more favorable overall or progress-free survival tendency than KALRN-mutated cancers (log-rank test, P=0.262, 0.067, 0.055, and 0.176 for Allen, Hugo, Riaz, and Rizvi cohorts, respectively) ( Figure 4D ). However, the correlation between KALRN mutations and overall survival was much less significant in TCGA melanoma or lung cancer cohorts not receiving immunotherapy ( Figure 4E ). These results indicate that the more favorable ICB therapy response in KALRN-mutated cancer cohorts is attributed to the elevated anti-tumor immune infiltrates and PD-L1 expression in this subtype, suggesting that the KALRN mutation is a predictive biomarker for the active response to ICB therapy.
4.Discussion
For the first time, we reported the significant role of KALRN mutations in promoting anti-tumor immunity and immunotherapeutic vulnerabilities in diverse cancer types. The reason why KALRN mutations can enhance anti-tumor immunity lies in that KALRN mutations increase tumor mutation load to create more neoantigens due to DNA damage repair deficiency. KALRNmutated cancers more highly express PD-L1, in addition to the increased anti-tumor immune infiltrates. Because both tumor-infiltrating lymphocyte density and PD-L1 expression are important factors in determining ICB therapy responsiveness 6, 23 , it is reasonable for KALRNmutated cancers to exhibit increased susceptibility to ICB therapy. This was evidenced in four cancer cohorts receiving ICB therapy ( Figure 4C&4D ). Furthermore, we investigated the underlying mechanism for KALRN mutations in enhancing anti-tumor immunity and immunotherapy response ( Figure 5 ). The significant association between KALRN mutations and heightened anti-tumor immunity may be attributed to that KALRN inactivation compromise the function of KALRN target Rho GTPases on regulating DNA damage repair pathways. The function of Rho GTPases on modulating DNA damage response has been revealed in previous studies 19 . In this study, we further demonstrated the important correlation between Rho GTPases and DNA damage repair pathways ( Figure 3C,   3D&3E ). Rho GTPases are involved in a wide variety of cellular functions and oncogenic processes, including cell cycle, cell death, cell migration, cell polarity, and cell adhesion 22, 24 .
Notably, previous studies have shown that inhibition of Rho GTPases could promote anti-tumor immune response by increasing the immune cytolytic activity of cytotoxic CD8+ T lymphocytes 25 . This is in accordance with our results showing that anti-tumor immune signatures grew stronger in the cancers harboring mutations of Rho GTPase genes ( Figure 3F ). Interestingly, we found that the cancers with mutations of Rho GTPase genes over-expressed PD-L1 in pan-cancer and multiple individual cancer types (Mann-Whitney U test, P<0.05). It suggests that mutations of Rho GTPase genes may favor ICB therapy response. Indeed, we found that the cancers harboring mutations of Rho GTPase genes showed higher ICB therapy response rates than those without such mutations in the four cancer cohorts receiving ICB therapy (42.86% versus 22.78% in Allen cohort, 70% versus 48.15% in Hugo cohort, 83.33% versus 25.64% in Riaz cohort, and 100% versus 45% in Rizvi cohort).
Conclusions
The KALRN mutation correlates with enhanced anti-tumor immunity and immunotherapy response and thus is a predictive biomarker for the response to immunotherapy. 
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